Undisclosed (stemECHO-derived)
Inflammatory Airway & Intestinal Diseases, Certain Cancers
PreclinicalActive
Key Facts
Indication
Inflammatory Airway & Intestinal Diseases, Certain Cancers
Phase
Preclinical
Status
Active
Company
About Tract Bio
Tract Bio is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA. Its core asset is the stemECHO platform, a proprietary technology for cloning and studying epithelial stem cells with high genetic fidelity, which it uses to discover novel therapeutic targets in cancer and inflammatory diseases. The company is building a preclinical pipeline focused on targeting pathogenic stem cells and utilizing a fibroblast-activated protein (FAP) prodrug strategy. Tract Bio's strategy involves internal pipeline development and seeking partnerships with established industry leaders.
View full company profile